Evidence map›Paper›PMID 34670356›Full record

ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2021

[Recommendations from Experts in the Management of Adverse Reactions 
to ALK Inhibitors (2021 Version)].

Ke Wang, Juan Li, Jianguo Sun, Li Li, Xi Zhang, Jianyong Zhang, Min Yu, Xianwei Ye, Ming Zhang, Yu Zhang and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 1 country.

Ke Wang *Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu 610041, China.
Juan Li *Department of Oncology, Sichuan Cancer Hospital, Chengdu 610041, China.
Jianguo Sun *Department of Oncology, Xinqiao Hospital, Army Military Medical University, Chongqing 400037, China.
Li LiDepartment of Respiratory and Critical Care Medicine, Army Special Medical Center (Daping Hospital), Chongqing 400042, China.
Xi ZhangDepartment of Oncology, Chengdu Third People's Hospital, Chengdu 610000, China.
Jianyong ZhangDepartment of Respiratory and Critical Care Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi 563000, China.
Min YuDepartment of Thoracic Oncology, West China Hospital of Sichuan University, Chengdu 610041, China.
Xianwei YeDepartment of Respiratory and Critical Care Medicine, Guizhou Provincial People's Hospital, Guiyang 550002, China.
Ming ZhangDepartment of Radiation Therapy, Yunnan Cancer Hospital, Kunming 650118, China.
Yu ZhangDepartment of Oncology, Guizhou Provincial People's Hospital, Guiyang 550002, China.
Wenxiu YaoDepartment of Oncology, Sichuan Cancer Hospital, Chengdu 610041, China.
Meijuan HuangDepartment of Thoracic Oncology, West China Hospital of Sichuan University, Chengdu 610041, China.
Guizhou Provincial People's Hospital · CNSichuan Cancer Hospital · CNSichuan University · CNChengdu Third People's Hospital · CNDaping Hospital · CNKunming Medical University · CNWest China Hospital of Sichuan University · CNXinqiao Hospital · CNZunyi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anaplastic lymphoma kinase (ALK) fusion gene, as a tumor driver gene, was crucial for the occurrence and development of non-small cell lung cancer (NSCLC). Recently, targeted ALK fusion gene has become the main treatment method for ALK-positive NSCLC. The first and second generation ALK inhibitors (ALKi), such as crizotinib, ceritinib, alectinib and ensartinib have been approved in China. However, there was no guidance for the management of ALKi adverse reactions. Therefore, this "Recommendations from experts in the management of adverse reactions to ALK inhibitors (2021 version)" has been summarized, led by Lung Cancer Professional Committee of Sichuan Cancer Society and Sichuan Medical Quality Control Center for Tumor Diseases, to provide practical and feasible strategies for clinical ALKi management specification of adverse reactions.
.

Indexed as

Carcinoma, Non-Small-Cell LungCrizotinibHumansLung NeoplasmsProtein Kinase InhibitorsReceptor Protein-Tyrosine KinasesCrizotinibProtein Kinase InhibitorsReceptor Protein-Tyrosine KinasesAdverse reactionsAnaplastic lymphoma kinase inhibitorsLung neoplasmsRecommendations

Identifiers

PMID34670356
PMCPMC8695243
OpenAlexW3206290912

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.